Lucentis Versus Mitomycin C During Glaucoma Surgery

This study has been completed.
Genentech, Inc.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Michael Pro, Wills Eye Identifier:
First received: February 20, 2008
Last updated: June 9, 2015
Last verified: June 2015
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.

Condition Intervention Phase
Drug: Ranibizumab
Drug: Mitomycin C 0.4 mg/ml
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Lucentis Versus Mitomycin C as Adjunctive Agent During Trabeculectomy Surgery

Resource links provided by NLM:

Further study details as provided by Wills Eye:

Primary Outcome Measures:
  • Adverse Events [ Time Frame: 1 day, 2 wks, 1, 3, 6 and 12 months ] [ Designated as safety issue: Yes ]
    Percentage of participants with ocular adverse events and other adverse events as identified by eye examination, physical examination, subject reporting and changes in vital signs.

Secondary Outcome Measures:
  • Efficacy [ Time Frame: 1 day, 2 wks, 1, 3, 6 and 12 months ] [ Designated as safety issue: Yes ]
    Mean change in intraocular pressure, number of glaucoma medications, bleb appearance based on the Indiana Bleb Appearance grading scale.

Enrollment: 24
Study Start Date: January 2008
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A: Ranibizumab 0.5mg (0.05mL) injection
Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriiorly to the limbus as an antifibrotic agent.
Drug: Ranibizumab
Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
Other Name: Lucentis
Active Comparator: B: Mitomycin C 0.4 mg/ml sponge
Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
Drug: Mitomycin C 0.4 mg/ml
Mitomycin C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
Other Name: MMC

Detailed Description:

This is an open-label, single center trial with two arms for patients who will undergo guarded filtration surgery to control glaucoma. The control will consist of patients randomly assigned to receive inter-operative mitomycin C 0.4 mg/ml which is applied in a standard fashion with a soaked pledget inserted in the sub-tenon's space during surgery. The study arm will consist of patients randomly assigned to receive a sub-tenon injection of Ranibizumab 0.5 mg/0.05mL with a 30 gauge needle on a tuberculin syringe at the termination of the surgery. No mitomycin C will be applied.

Post operative follow-up will consist of a minimum of 6 visits over a one year period.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 yrs or older
  • patients requiring first time glaucoma filtering surgery
  • phakic or pseudophakic
  • must provide written informed consent and comply with study assignments

Exclusion Criteria:

  • Pregnant, lactation or premenopausal women not using adequate contraception.
  • Previous glaucoma surgery, tube shunt surgery, pars plana vitrectomy, scleral buckle, penetrating keratoplasty.
  • Abnormality preventing reliable applanation tonometry in each eye.
  • Current infection or inflammation in either eye.
  • Enrolled in another investigational study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00626782

United States, Pennsylvania
Wills Eye Hospital, Glaucoma Service
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Wills Eye
Genentech, Inc.
Novartis Pharmaceuticals
Principal Investigator: Michael J Pro, MD Wills Eye Institute
  More Information

Pro, MJ, Sawchyn AK, Ichhpujani P, Wizov S, Moster MR, Spaeth GL. Intraoperative Ranibizumab versus Mitomycin-C in Primary Trabeculectomy - A Pilot Study. ARVO E-abstract 619/A463 2010.

Responsible Party: Michael Pro, Principal Investigator, Wills Eye Identifier: NCT00626782     History of Changes
Other Study ID Numbers: IRB#07-819, rhuFAB v2
Study First Received: February 20, 2008
Results First Received: February 11, 2015
Last Updated: June 9, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Wills Eye:
glucoma filtering surgery
mitomycin C
patients requiring first time glaucoma filtering surgery

Additional relevant MeSH terms:
Eye Diseases
Ocular Hypertension
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses processed this record on November 30, 2015